- Home
- TXMD vs HIND Comparison
TXMD vs HIND Comparison
Compare TXMD & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- HIND
- Stock Information
- Founded
- TXMD 2008
- HIND N/A
- Country
- TXMD United States
- HIND United States
- Employees
- TXMD N/A
- HIND N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- HIND
- Sector
- TXMD Health Care
- HIND
- Exchange
- TXMD Nasdaq
- HIND Nasdaq
- Market Cap
- TXMD 12.3M
- HIND 10.3M
- IPO Year
- TXMD N/A
- HIND 2016
- Fundamental
- Price
- TXMD $1.23
- HIND $5.41
- Analyst Decision
- TXMD
- HIND
- Analyst Count
- TXMD 0
- HIND 0
- Target Price
- TXMD N/A
- HIND N/A
- AVG Volume (30 Days)
- TXMD 506.6K
- HIND N/A
- Earning Date
- TXMD 11-12-2025
- HIND N/A
- Dividend Yield
- TXMD N/A
- HIND N/A
- EPS Growth
- TXMD N/A
- HIND N/A
- EPS
- TXMD N/A
- HIND N/A
- Revenue
- TXMD $2,559,000.00
- HIND N/A
- Revenue This Year
- TXMD $427.09
- HIND N/A
- Revenue Next Year
- TXMD N/A
- HIND N/A
- P/E Ratio
- TXMD N/A
- HIND N/A
- Revenue Growth
- TXMD 156.93
- HIND N/A
- 52 Week Low
- TXMD $0.70
- HIND N/A
- 52 Week High
- TXMD $2.44
- HIND N/A
- Technical
- Relative Strength Index (RSI)
- TXMD 59.44
- HIND 44.08
- Support Level
- TXMD $1.20
- HIND $5.31
- Resistance Level
- TXMD $1.37
- HIND $5.70
- Average True Range (ATR)
- TXMD 0.12
- HIND 0.35
- MACD
- TXMD 0.02
- HIND 0.12
- Stochastic Oscillator
- TXMD 29.85
- HIND 70.71
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.